79 related articles for article (PubMed ID: 23153504)
1. Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature.
Gérard JP; Baulieux J; Doyen J; Gal J; Letouze E; Olschwang S; Chapet O; Romestaing P
Cancer Radiother; 2012 Dec; 16(8):688-96. PubMed ID: 23153504
[TBL] [Abstract][Full Text] [Related]
2. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
[TBL] [Abstract][Full Text] [Related]
4. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
5. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
6. Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival.
Wieder HA; Rosenberg R; Lordick F; Geinitz H; Beer A; Becker K; Woertler K; Dobritz M; Siewert JR; Rummeny EJ; Stollfuss JC
Radiology; 2007 Jun; 243(3):744-51. PubMed ID: 17463134
[TBL] [Abstract][Full Text] [Related]
7. B1 versus B2 Dukes stage rectal cancer: prospective evaluation of 87 patients in a single institution and quest for re-evaluation of the current protocol.
Costea R; Zarnescu NO; Vasiliu EC; Minca D; Sajin M; Neagu S
Hepatogastroenterology; 2012; 59(113):98-100. PubMed ID: 22251525
[TBL] [Abstract][Full Text] [Related]
8. The surgeon as prognostic factor for local recurrence and survival in the anal sphincter preservation for mid-rectal cancer.
Luna-Pérez P; Reyna Huelga A; Labastida Almendaro S; Rodríguez-Coria DF; González Macouzet J; Delgado Gallardo S
Rev Invest Clin; 1999; 51(4):205-13. PubMed ID: 10546501
[TBL] [Abstract][Full Text] [Related]
9. Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
Eriksen MT; Wibe A; Haffner J; Wiig JN;
Dis Colon Rectum; 2007 Feb; 50(2):156-67. PubMed ID: 17180256
[TBL] [Abstract][Full Text] [Related]
10. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
[TBL] [Abstract][Full Text] [Related]
11. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
13. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
14. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
[TBL] [Abstract][Full Text] [Related]
15. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
[TBL] [Abstract][Full Text] [Related]
16. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.
Gavioli M; Luppi G; Losi L; Bertolini F; Santantonio M; Falchi AM; D'Amico R; Conte PF; Natalini G
Dis Colon Rectum; 2005 Oct; 48(10):1851-7. PubMed ID: 16132481
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.
Capirci C; Valentini V; Cionini L; De Paoli A; Rodel C; Glynne-Jones R; Coco C; Romano M; Mantello G; Palazzi S; Mattia FO; Friso ML; Genovesi D; Vidali C; Gambacorta MA; Buffoli A; Lupattelli M; Favretto MS; La Torre G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):99-107. PubMed ID: 18407433
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.
Song S; Hong JC; McDonnell SE; Koong AC; Minsky BD; Chang DT; Liauw SL
Ann Surg Oncol; 2012 Aug; 19(8):2471-6. PubMed ID: 22327251
[TBL] [Abstract][Full Text] [Related]
19. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
Gunderson LL; Sargent DJ; Tepper JE; Wolmark N; O'Connell MJ; Begovic M; Allmer C; Colangelo L; Smalley SR; Haller DG; Martenson JA; Mayer RJ; Rich TA; Ajani JA; MacDonald JS; Willett CG; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1785-96. PubMed ID: 15067027
[TBL] [Abstract][Full Text] [Related]
20. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
